Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations
U.S. RESEARCH ROUNDUP- CME Group, M&T Bank, PNC Financial Services
Brief: Equillium Inc Selling Stockholder May Offer Up To 18.9 Million Shares Of Common Stock
Brief: Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Equillium reports lower-than-expected Q4 net loss
Brief: Equillium Reports Inducement Grants Under Nasdaq Listing Rule
Brief: Equillium Files For Mixed Shelf Of Up To $250 Million - SEC Filing
Autoimmune disorders therapeutics developer Equillium posts narrower than expected Q3 loss
Brief: Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Equillium Announces Leadership And Corporate Updates
Brief: Equillium Files Prospectus For $75 Million Share Offering - SEC Filing
Brief: Equillium Files For Offering Of Up To 52.63 Million Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP-Analog Devices, Autodesk, Salesforce
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Inc expected to post a loss of 18 cents a share - Earnings Preview